Eckert & Ziegler Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Harald Hasselmann
Algemeen directeur
€475.2k
Totale compensatie
| Percentage CEO-salaris | 65.7% |
| Dienstverband CEO | 7.8yrs |
| Eigendom CEO | n/a |
| Management gemiddelde ambtstermijn | 4.8yrs |
| Gemiddelde ambtstermijn bestuur | 5.7yrs |
Recente managementupdates
Recent updates
Eckert & Ziegler SE's (ETR:EUZ) Share Price Could Signal Some Risk
Aug 08
Does Eckert & Ziegler (ETR:EUZ) Have A Healthy Balance Sheet?
Jul 17Why We Think Eckert & Ziegler SE's (ETR:EUZ) CEO Compensation Is Not Excessive At All
Jun 20Investors Met With Slowing Returns on Capital At Eckert & Ziegler (ETR:EUZ)
Jun 05Is Now An Opportune Moment To Examine Eckert & Ziegler SE (ETR:EUZ)?
May 13Eckert & Ziegler SE (ETR:EUZ) Investors Are Less Pessimistic Than Expected
Apr 27Here's Why Eckert & Ziegler (ETR:EUZ) Can Manage Its Debt Responsibly
Apr 12Slowing Rates Of Return At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Leave Little Room For Excitement
Mar 06What Eckert & Ziegler Strahlen- und Medizintechnik AG's (ETR:EUZ) P/E Is Not Telling You
Jan 04Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Has A Pretty Healthy Balance Sheet
Dec 20Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Hasn't Managed To Accelerate Its Returns
Nov 15What Is Eckert & Ziegler Strahlen- und Medizintechnik AG's (ETR:EUZ) Share Price Doing?
Oct 01A Look At The Intrinsic Value Of Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)
Aug 22These 4 Measures Indicate That Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is Using Debt Reasonably Well
Jul 16Is It Time To Consider Buying Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Jun 22The Return Trends At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Look Promising
May 17Is Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ) Potentially Undervalued?
Mar 20Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Returns Have Hit A Wall
Jan 24We Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Can Stay On Top Of Its Debt
Oct 27Is It Time To Consider Buying Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Oct 05Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Has Some Way To Go To Become A Multi-Bagger
Aug 21Is Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) A Risky Investment?
Jul 21Is There Now An Opportunity In Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Jun 13Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Will Pay A Larger Dividend Than Last Year At €0.50
May 13Returns At Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Are On The Way Up
May 09Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Dividend Will Be Increased To €0.50
Apr 24Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Dividend Will Be Increased To €0.50
Mar 27Do Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Earnings Warrant Your Attention?
Mar 25When Should You Buy Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ)?
Feb 17Investors Will Want Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Growth In ROCE To Persist
Jan 31Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Deserve Your Attention Today
Dec 13Eckert & Ziegler Strahlen- und Medizintechnik's (ETR:EUZ) Returns On Capital Are Heading Higher
Nov 01Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Deserve Your Attention Today
Sep 14Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Might Have The Makings Of A Multi-Bagger
Jul 29Here's Why I Think Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is An Interesting Stock
Jun 11Eckert & Ziegler Strahlen- und Medizintechnik (ETR:EUZ) Is Experiencing Growth In Returns On Capital
Apr 30The Case For Eckert & Ziegler Strahlen- und Medizintechnik AG (ETR:EUZ): Could It Be A Nice Addition To Your Dividend Portfolio?
Apr 02Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | €38m |
| Mar 31 2024 | n/a | n/a | €34m |
| Dec 31 2023 | €475k | €312k | €30m |
| Sep 30 2023 | n/a | n/a | €31m |
| Jun 30 2023 | n/a | n/a | €29m |
| Mar 31 2023 | n/a | n/a | €30m |
| Dec 31 2022 | €543k | €250k | €31m |
| Sep 30 2022 | n/a | n/a | €27m |
| Jun 30 2022 | n/a | n/a | €27m |
| Mar 31 2022 | n/a | n/a | €27m |
| Dec 31 2021 | €509k | €216k | €35m |
| Sep 30 2021 | n/a | n/a | €33m |
| Jun 30 2021 | n/a | n/a | €31m |
| Mar 31 2021 | n/a | n/a | €30m |
| Dec 31 2020 | €400k | €209k | €21m |
| Sep 30 2020 | n/a | n/a | €21m |
| Jun 30 2020 | n/a | n/a | €22m |
| Mar 31 2020 | n/a | n/a | €21m |
| Dec 31 2019 | €366k | €204k | €22m |
| Sep 30 2019 | n/a | n/a | €22m |
| Jun 30 2019 | n/a | n/a | €21m |
| Mar 31 2019 | n/a | n/a | €20m |
| Dec 31 2018 | €347k | €196k | €16m |
| Sep 30 2018 | n/a | n/a | €16m |
| Jun 30 2018 | n/a | n/a | €14m |
| Mar 31 2018 | n/a | n/a | €11m |
| Dec 31 2017 | €345k | €189k | €12m |
Compensatie versus markt: De totale vergoeding ($USD 514.91K ) Harald } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.44M ).
Compensatie versus inkomsten: De vergoeding van Harald is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Harald Hasselmann (57 yo)
7.8yrs
Tenure
€475,161
Compensatie
Dr. Harald Hasselmann is Deputy Chairman of the Supervisory Board of Pentixapharm Holding AG from February 15, 2024. Dr. Hasselmann is Chairman of the Executive Board of Medical Segment at Eckert & Ziegler...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman of the Executive Board of Medical Segment | 7.8yrs | €475.16k | geen gegevens | |
| President of Eckert and Ziegler Isotope Products Inc. & Member of Executive Board | 1.4yrs | €1.12m | geen gegevens | |
| Member of Executive Board of Asia Business | 1.8yrs | €181.48k | geen gegevens | |
| Head of Intragroup Services | 12.8yrs | geen gegevens | geen gegevens | |
| Head of Segment Isotope Products | less than a year | geen gegevens | geen gegevens | |
| Managing Director of Eckert & Ziegler Cesio s.r.o. | 10.8yrs | geen gegevens | geen gegevens | |
| Vice President of Eckert & Ziegler Isotope Products Inc. | no data | geen gegevens | geen gegevens |
4.8yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van EUZ wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman of the Supervisory Board | less than a year | €700.71k | 0.000020% € 162.9 | |
| Member of Supervisory Board | 5.5yrs | €37.92k | geen gegevens | |
| Member of Supervisory Board | 5.8yrs | €34.58k | geen gegevens | |
| Deputy Chairman of the Supervisory Board | 10.3yrs | €39.00k | geen gegevens | |
| Member of Supervisory Board | 1.9yrs | geen gegevens | geen gegevens | |
| Member of Supervisory Board | 7.5yrs | €37.67k | geen gegevens |
5.7yrs
Gemiddelde duur
67.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van EUZ wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.7 jaar).